Scil Proteins, a German private biotech company specialising in the research, development and production of recombinant proteins, has appointed Ulrich Haupts as its new chief scientific officer. As of 1 October, he will replace Arnd Steuernagel.
Haupts was previously director of protein optimisation at Bayer Healthcare, a position he has held for the last three years. Prior to that, he spent seven years at Direvo Biotech (which was subsequently acquired by Bayer Schering Pharma in 2008) as department head of assay development and later, as vp of r&d biopharmaceuticals.
Dr Haupts also worked for three years at SmithKline Beecham UK in the New Assay Technology group.
Scil Proteins appoints chief scientific officer
Ulrich Haupts joins the biotech firm from Bayer Healthcare
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally